Learn more about our recently-funded TechAdvance and TechXpress projects.
Finite element simulations are used pervasively in industries such as aviation, energy, and manufacturing to design engineering products. This project seeks to significantly accelerate the pace of engineering design by coupling neural networks with the finite element method, thereby enabling development of efficient surrogate models that replace traditional simulations.
This research seeks to prove a technology concept that could transform protein drug administration by empowering a patient’s own body to be a “living pharmacy”. If realized, this user-controlled wireless technology to control gene expression can minimize cost and maximize treatment adherence for potentially millions of patients in need.
Our nanotechnology is directed towards mitigating neuroinflammation and the associated neurodegeneration within the brain. Once optimized and appropriately harnessed, our technology has the mechanism of action to halt the progressive loss of neurons. This is achieved by arresting excessive neuroinflammation and promoting the natural clearance of neurotoxic proteins such as amyloid beta.
Blue organic light-emitting diodes (OLEDs) used in displays and lighting technologies have significantly lower efficiency and stability compared with green and red OLEDs. This project will improve blue OLED efficiency and operational stability by increasing light extraction and reducing degradation pathways in the organic semiconductor emissive layer.
This project aims to develop an autonomous navigation system for wheelchairs, enhancing user independence and safety while reducing caregiver workload. It targets individuals with mobility impairments, elderly users, and those with progressive conditions, using system-level design of sensors, navigation, and control technologies for safe navigation in various environments.
Our objective is to optimize an inhibitor of the malaria-causing parasite, Plasmodium. We will use structure-guided design to optimize the molecule’s potency against its target kinase. The resulting medicinal chemistry program will yield highly potent and selective inhibitors of Plasmodium suitable for further development of an anti-malarial drug.